Transaction #32742 · Form 4 · 0001628280-26-065566
Pacira BioSciences, Inc. · Exercise / conversion · Common Stock
Pacira BioSciences, Inc. · Transacted October 8, 2026 · Filed October 9, 2026
What does this filing report?
An SEC Form 4 filing for Pacira BioSciences, Inc. records an exercise / conversion involving Common Stock on October 8, 2026. The reported quantity was 6,000. The filing date is October 9, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Pacira BioSciences, Inc.
- Company CIK
- 0001396814
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 6,000
- Reported price
- 32.35
- Reference value
- 194,100
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 68,284.242
- Ownership description
- Not reported
- SEC acceptance time
- Oct 9, 2026, 7:07 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- RIKER LAUREN ↗
Senior Vice President, Finance
CIK 0001545439
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
- F2
- The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.